The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
The present invention relates to compounds of formula (I):
or a pharmaceutically acceptable salt thereof, wherein A
1
, A
2
, L
1
and B are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A
4
hydrolase (LTA
4
H) and treating LTA
4
H related disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.